In this photo taken July 9, 2015, a man cycles near the headquarters of Gilead Sciences in Foster City, Calif. A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure. The report released Tuesday by the Senate Finance Committee concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease. (AP Photo/Eric Risberg)
In this photo taken July 9, 2015, a man cycles near the headquarters of Gilead Sciences in Foster City, Calif. A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure. The report released Tuesday by the Senate Finance Committee concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease. (AP Photo/Eric Risberg) Eric Risberg AP
In this photo taken July 9, 2015, a man cycles near the headquarters of Gilead Sciences in Foster City, Calif. A bipartisan investigation by U.S. senators finds that the makers of a breakthrough drug for hepatitis C infection put profits before patients in pricing the $1,000-per-pill cure. The report released Tuesday by the Senate Finance Committee concludes that California-based Gilead Sciences was focused on maximizing revenue even as its own analysis showed a lower price would allow more patients to be treated for the liver-wasting disease. (AP Photo/Eric Risberg) Eric Risberg AP

Report: Drug maker was focused on profits, not patients

December 01, 2015 05:01 PM

More Videos